Literature DB >> 7989750

H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.

C L Sentman1, M Y Olsson, M Salcedo, P Höglund, U Lendahl, K Käre.   

Abstract

In vivo murine NK cells are known to mediate graft rejection in allogenic as well as in "F1 anti-parental" situations. We have studied an in vitro system based on rIL-2-activated spleen cells and Con A lymphoblast targets in relation to the genetics of F1 hybrid resistance and NK cell activity. We demonstrate that NK cells in this in vitro model are regulated by MHC class I genes in an allele-specific manner at the level of the effector and the target. Using rIL-2-activated effector cells from nude C57BL/6 (B6) and BALB/c mice, we observed no killing of MHC syngeneic lymphoblasts. However, B6 as well as BALB/c lymphoblasts were killed by effector cells from allogeneic nude mice as well as by cells from (BALB/c x B6)F1 hybrids. Experiments that used D8 mice (which carry an H-2Dd transgene on B6 background) and beta 2-m-/- mice demonstrated a direct role for MHC class I molecules at the effector as well as at the target cell level: H-2Dd transgenic effector cells with the typical NK phenotype 3A4+/CD8- killed B6 blasts, but expression of the corresponding H-2Dd transgene in the target lymphoblasts protected them from killing. By using transgenic mice carrying exon shuffled MHC class I transgenes, the protective effect of the H-2Dd molecule was mapped to the alpha 1/alpha 2 domains. MHC class I-deficient lymphoblasts from beta 2-m-/- mice were killed by effectors from all strains of mice, including those matched for MHC. The H-2 class I allele-specific protection in this in vitro assay was observed for lymphoblasts but not for tumor cells, despite the fact that these tumor cells are protected in an allele-specific manner in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989750

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Ly49A inhibitory receptors redistribute on natural killer cells during target cell interaction.

Authors:  M Eriksson; J C Ryan; M C Nakamura; C L Sentman
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.

Authors:  M R Daws; M Eriksson; L Oberg; A Ullén; C L Sentman
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.

Authors:  Andreas Lundqvist; J Philip McCoy; Leigh Samsel; Richard Childs
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

4.  The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes.

Authors:  C Frohn; P Schlenke; H Kirchner
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

5.  The virus-specific and allospecific cytotoxic T-lymphocyte response to lymphocytic choriomeningitis virus is modified in a subpopulation of CD8(+) T cells coexpressing the inhibitory major histocompatibility complex class I receptor Ly49G2.

Authors:  C D Peacock; M Y Lin; J R Ortaldo; R M Welsh
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

Authors:  Tong Zhang; Bethany A Lemoi; Charles L Sentman
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

7.  Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene.

Authors:  M H Johansson; C Bieberich; G Jay; K Kärre; P Höglund
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

8.  Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets.

Authors:  M Eriksson; G Leitz; E Fällman; O Axner; J C Ryan; M C Nakamura; C L Sentman
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

9.  Elimination in vivo of developing T cells by natural killer cells.

Authors:  Eckart Schott; Roberto Bonasio; Hidde L Ploegh
Journal:  J Exp Med       Date:  2003-10-20       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.